Postpartum Depression Clinical Trial
Official title:
An Open-label Study of Escitalopram in the Treatment of Postpartum Depression
This will be an 8-week, open-label trial evaluating the efficacy of escitalopram as
monotherapy in the treatment of patients with postpartum depression (PPD). The acute phase
of the study will consist of an 8 week treatment phase. Treatment of eligible participants
will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based
on the presence of depressive symptoms and side effects up to a maximum of 20mg/day.
Study objectives are:
1. to investigate the efficacy of escitalopram in the treatment of PPD.
2. to assess the effects of escitalopram on patients quality of life.
Major Depression Postpartum Onset (PPD) is a chronic relapsing illness which affects not
only maternal mood but also the baby and family. Therefore, it is critical to aim for timely
intervention once the diagnosis is made. Studies have shown that antidepressant medications
are effective in treatment for moderate to severe PPD. Common reasons for noncompliance and
discontinuation of antidepressant medications in the postpartum period are the side effects
associated with different antidepressants. To choose an antidepressant medication with
proven efficacy and a tolerable side effect profile is key in order to maximize adherence to
pharmacotherapy.
A number of studies have been published that highlight the efficacy of escitalopram in the
treatment of Major Depressive Disorder (MDD). However, there has been no research to date
investigating the effectiveness of escitalopram in the treatment of PPD.
Based upon the preliminary clinical observations in our tertiary care program (Provincial
Reproductive Mental Health Program) where a postpartum depressed population is frequently
treated with antidepressant medications, compliance with escitalopram has been impressive.
Therefore, we propose to conduct an open-label study with escitalopram in postpartum
depressed, non-lactating mothers to confirm our clinical observation.
Hypotheses:
i) Escitalopram will be effective in the treatment of Postpartum Depression and ii)
Escitalopram will be effective in increasing the quality of life of participants.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06348316 -
Early Half Swaddling and Kangaroo Care Practices on Maternal Sleep Quality and Postpartum Depression in Term Babies
|
N/A | |
Completed |
NCT05322161 -
Yoga in the NICU for Parents Study
|
N/A | |
Withdrawn |
NCT03709004 -
Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression
|
N/A | |
Completed |
NCT06305325 -
Coparenting Intervention to Prevent Postpartum Depression
|
N/A | |
Not yet recruiting |
NCT05055674 -
The Effects of Motherly on Postpartum Depression
|
N/A | |
Enrolling by invitation |
NCT02323152 -
PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK
|
N/A | |
Not yet recruiting |
NCT01658098 -
Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez
|
N/A | |
Completed |
NCT00961402 -
The Effect of Exercise on Preventing PostPartum Depression
|
Phase 2 | |
Completed |
NCT01312883 -
Mothers Avoiding Depression Through Empowerment Intervention Trial
|
N/A | |
Completed |
NCT00360204 -
Improving Health Outcomes for New Mothers and Babies
|
Phase 3 | |
Unknown status |
NCT00548743 -
Translating Research Into Practice for Postpartum Depression
|
N/A | |
Completed |
NCT04146025 -
Nurtured in Nature
|
N/A | |
Not yet recruiting |
NCT06442774 -
MamaConecta: Digital Tool for Maternal Mental Health
|
N/A | |
Recruiting |
NCT05137925 -
Mindful Moms: Mechanisms of Mindfulness-based Cognitive Therapy During Pregnancy and Postpartum
|
N/A | |
Not yet recruiting |
NCT05299398 -
Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone
|
Phase 1 | |
Completed |
NCT04925765 -
Virtual Reality Biofeedback for Postpartum Anxiety and Depression
|
N/A | |
Recruiting |
NCT06053515 -
Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication
|
N/A | |
Completed |
NCT04037085 -
Ketamine to Improve Recovery After Cesarean Delivery - Part 1
|
Phase 2 | |
Completed |
NCT05059600 -
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
|
Phase 4 | |
Completed |
NCT06136520 -
The Effect of Baby Massage Training Given to Pregnant Women on Maternal Attachment and Postpartum Depression
|
N/A |